NCT06188208 - A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions

Advanced Solid TumorsAdvanced Hematologic Tumors

Interventions

DRUG

VVD-130850

Oral tablets

DRUG

Pembrolizumab

IV infusion

Trial Locations (20)

22031

NEXT Virginia, Fairfax

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

75039

NEXT Dallas, Irving

77030

MDACC, Houston

78299

NEXT San Antonio, San Antonio

78758

NEXT Austin, Austin

84112

University of Utah Huntsman Cancer Institute, Salt Lake City

90027

California Research Institute, Los Angeles

Unknown

Blacktown Hospital, Blacktown

Orange Health Service, Orange

Gold Coast University Hospital, Southport

Cancer Research South Australia, Adelaide

ICON Cancer Research, South Brisbane

START Barcelona Hospital HM Nou Delfos, Barcelona

Vall d'Hebron, Barcelona

Hospital Universitario 12 de Octubre, Madrid

NEXT Madrid, Madrid

START Madrid CIOCC, Madrid

Start Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

All Listed Sponsors

lead

Vividion Therapeutics, Inc.

INDUSTRY